These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37940719)

  • 1. Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
    Fan S; Wang L; Lu Y; Li Z
    Ann Hematol; 2024 Feb; 103(2):525-532. PubMed ID: 37940719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
    Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
    J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
    Wang J; Zhang Y; Zu Y; Li Z; Li M; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):110-4. PubMed ID: 27014979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report.
    Liu T; Wang C; Fu Y; Yang YP; Tan YH
    Medicine (Baltimore); 2024 Jul; 103(29):e38985. PubMed ID: 39029009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
    Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
    Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
    Assi R; Kantarjian H; Short NJ; Daver N; Takahashi K; Garcia-Manero G; DiNardo C; Burger J; Cortes J; Jain N; Wierda W; Chamoun S; Konopleva M; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):897-901. PubMed ID: 28927784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
    Nguyen TTT; Tamai M; Harama D; Kagami K; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
    Int J Hematol; 2022 Oct; 116(4):534-543. PubMed ID: 35524023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
    Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X
    J Hematol Oncol; 2022 Aug; 15(1):113. PubMed ID: 35982483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia.
    Li X; Zhang J; Liu F; Liu T; Zhang R; Chen Y; Guo Y; Fang Y; Xu X; Pui CH; Zhu X
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):660-666. PubMed ID: 37301632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
    Egan DN; Beppu L; Radich JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
    Chen H; Xu LP; Zhang XH; Wang Y; Chen YH; Yan CH; Cheng YF; Han W; Chen Y; Qin YZ; Liu Y; Chang YJ; Liu KY; Huang XJ
    Leuk Res; 2022 Oct; 121():106930. PubMed ID: 36007342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olverembatinib: First Approval.
    Dhillon S
    Drugs; 2022 Mar; 82(4):469-475. PubMed ID: 35195876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.
    Takahashi N; Miura M; Scott SA; Niioka T; Sawada K
    J Hematol Oncol; 2012 May; 5():23. PubMed ID: 22587422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
    Shen HJ; He J; Qiu QC; Cen JN; Pan JL; Yao L; Ding ZX; Chen Y; Chen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):21-5. PubMed ID: 23597459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome- and metabolome-based candidate mechanism of BCR-ABL-independent resistance to olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yin Z; Liao M; Yan R; Li G; Ou R; Liu Z; Zhong Q; Shen H; Zhu Y; Xie S; Zhang Q; Liu S; Huang J
    Funct Integr Genomics; 2023 Jan; 23(1):53. PubMed ID: 36717477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study.
    Tan X; Wen Q; Chen G; Wan K; Liu X; Ma YY; Wang MH; Zhang X; Zhang C
    Anticancer Drugs; 2023 Apr; 34(4):599-604. PubMed ID: 36730312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.